Vectura Group PLC (VEC.L) News| Reuters.com
Edition:
United States

Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

156.00GBp
24 Jun 2016
Change (% chg)

-4.70p (-2.92%)
Prev Close
160.70p
Open
155.90p
Day's High
160.00p
Day's Low
151.90p
Volume
2,191,313
Avg. Vol
1,205,444
52-wk High
200.10p
52-wk Low
145.30p

Select another date:

Fri, Jun 10 2016

BRIEF-HBM Healthcare Investments: merger of Skyepharma and Vectura effective

* Recommended all share merger of Skyepharma and Vectura becomes effective

BRIEF-Vectura FY core earnings rise 43 pct

* EBITDA(1) up 43% to £23.2m (2014/15: £16.2m) Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

BRIEF-Vectura & Propeller Health announce collaboration

* Vectura and propeller health announce collaboration to develop digitally-connected inhalers to address chronic respiratory diseases Source text for Eikon: Further company coverage:

BRIEF-Vectura Group says CMA not to investigate Vectura-Skyepharma merger

* CMA has confirmed that proposed recommended all share merger of Vectura and Skyepharma does not qualify for investigation

BRIEF-UK's CMA says no relevant merger situation in Vectura-Skyepharma deal

* UK's CMA says decided that a relevant merger situation has not been created in anticipated acquisition by Vectura Group Plc of Skyepharma Plc Source text for Eikon:

Drugmaker Vectura Group to buy SkyePharma

March 16 Drugmaker Vectura Group said on Wednesday it would buy SkyePharma Plc in an all-stock deal that would give it SkyePharma's drug delivery platform.

BRIEF-HBM Healthcare Investments says Skyepharma to merge with Vectura group

* Under the terms of the proposed merger, Skyepharma shareholders will be entitled to receive 2.7977 new Vectura shares for every Skyepharma share

BRIEF-Vectura Group to buy Skyepharma for 441.3 million stg

* Vectura Group and Skyepharma Plc have reached agreement on terms of a recommended merger between Vectura and Skyepharma

BRIEF-Vectura says clinical study report for asthma therapy VR315 now final

* Next planned milestone and announcement scheduled for this programme is $10 million due to be paid upon acceptance for filing of ANDA by FDA

BRIEF-Vectura completes clinical trial for asthama therapy

* Is eligible to receive a further $23 mln upon achievement of future pre-determined development milestones on VR315 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

Select another date: